Psychedelics Archives - Page 2 of 5

Monday Apr 04, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022

Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences ConferenceIn presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the yearDuring a recent interview on The Jesse Tee Show, Stang noted the company intends…

Monday Mar 28, 2022 - 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addictionMydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trialsThe company is targeting nicotine addiction…

Friday Mar 25, 2022 - 9:00 am

Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Makes Psychedelic Treatment More Accessible with Opening of New Reno Clinic

Following the acquisition of KWC back in November 2021, Delic Holdings Corp set out to open additional state-of-the-art ketamine infusion treatment clinics over the course of 18 monthsThe company has just announced the opening of its second clinic in Nevada in a move that will serve both local patients and those in larger California markets without access to affordable in-state providersDelic is still set to…

Thursday Mar 24, 2022 - 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year.Psilocybin could lead to significant, durable improvements in depression.Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes…

Thursday Mar 17, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Aiming to Reach Millions of Mental Health Patients with Effective, Affordable Ketamine Treatments

Mental health conditions affect millions of people globally, some of whom are resistant to existing treatmentsIn the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatmentDelic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes…

Thursday Mar 17, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic optionsGrowing number of cities, states looking at decriminalizing use of psychedelic medicineCybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a…

Wednesday Mar 16, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leverages Research to Promote Mental Health

Delic Holdings Corp, a leader in new medicines and treatments for a modern world, understands that research is integral for both the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for the treatment of mental health issuesDr. Markus Roggen, President and CSO of Delic Labs, recently spoke at this year’s Emerald Conference, and has reiterated the importance of leveraging AI…

Thursday Mar 03, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patentPatent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compoundsCYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office…

Monday Feb 28, 2022 - 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Tackles Pandemic-era Mental Health Crises with Product R&D and Educational Efforts for the Application of Psychedelics Technology

Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needsDelic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet…

Monday Feb 28, 2022 - 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005

Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compoundsMydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nauseaThe company is excited about this finding, terming it one of the many…

Friday Feb 25, 2022 - 9:15 am

Nemaura Medical Inc. (NASDAQ: NMRD) Publishes 3QFY2022 Results; Company Reports its Inaugural Quarterly Revenues

Nemaura Medical has recently reported its 3QFY2022 (4QCY2021) results, with the company recognizing its inaugural revenues of $183,628 over the quarterThe company also announced that it held $23 million in cash reserves as of the end of the quarter, which should amply cover its cash requirements over the coming monthsNemaura Medical seized upon the opportunity to update investors on their ongoing operational highlights, which include…

Wednesday Feb 23, 2022 - 10:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSDThese results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizonMydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academicsIn a recent interview, company…

Tuesday Feb 22, 2022 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare

The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available83% of Americans living with these conditions are open to trying out alternative treatmentsDelic seeks to capitalize on this growing…

Tuesday Feb 15, 2022 - 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addictionMydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment optionsThe license allows Mydecine to provide psilocybin and MDMA…

Tuesday Feb 15, 2022 - 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion planIn a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made availableStudies such as these are helping Delic drive the conversation on psychedelics forwardThe company seeks to take this…

Monday Feb 14, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technologyKernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experienceCYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward…

Friday Feb 11, 2022 - 9:15 am

Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Delic Labs to Present Latest Results and Insights from Its Extensive Experimental Studies on Cannabis Extraction at the Emerald Conference on February 28

Delic Lab’s President and Chief Science Officer, Dr. Markus Roggen, will present at the upcoming Emerald Conference on February 28Delic Labs is a federally licensed research laboratory operating as part of the Delic Holdings ecosystemThe laboratory focuses on extraction optimization, analytical testing, and chemical product and process development and is likely to continue supporting the cannabis industry with the latest technology and services as the…

Wednesday Feb 02, 2022 - 12:38 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compoundMydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwideThe LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug…

Monday Jan 31, 2022 - 1:03 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics.Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously missing. Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative…

Thursday Jan 27, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuseWell+Good says psychedelics “poised to change the course of mental health treatment”Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://ibn.fm/3ZGGE). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE…

Tuesday Jan 25, 2022 - 12:15 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Reports Findings of Commissioned Study Showing a Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment for Select Mental Conditions

The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSDThe survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were…

Monday Jan 24, 2022 - 12:28 pm

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapyThe products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy supportThe planned launch follows an amendment to federal regulations allowing physicians to…

Friday Jan 21, 2022 - 10:37 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Corporate Update Points to Profitability in 2022 and Beyond

In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MMGoing into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 monthsDelic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditionsIts management is confident that the foundations laid down so…

Wednesday Jan 19, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021Approvals, licenses, expansions and growth all essential pieces of Cybin successCYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off…

Wednesday Jan 19, 2022 - 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and developmentHe noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new yearMr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly…

Wednesday Jan 12, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disordersApproval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental healthAnxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received…

Monday Jan 10, 2022 - 12:19 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expandingThe use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions…

Monday Jan 10, 2022 - 12:02 pm

Congressman Calls for Liberalized Access to Psilocybin; Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Positions for Growth Within Psychedelics Sector

Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatmentAlthough 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEAChange seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and OaklandDelic Corp has…

Monday Jan 10, 2022 - 10:22 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelicsThe company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscapeCYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin…

Thursday Jan 06, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical developmentCYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”)CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen…

Wednesday Jan 05, 2022 - 11:47 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessationThe company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risksTwo previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as…

Tuesday Jan 04, 2022 - 10:32 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolioOnce issued, patent may have opportunity to cover a broad range of claimsAnxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance…

Monday Jan 03, 2022 - 1:18 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Joins Gamechangers LIVE Podcast; Shares Views on the Evolution of the Psychedelics Industry

Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platformsDelic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic…

Wednesday Dec 29, 2021 - 11:37 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) to Open 2 New Ketamine Infusion Clinics; Co-Founder and CEO Matt Stang Reveals Investor Relations Efforts

Delic Holdings subsidiary, Ketamine Wellness Centers, announced plans to open two new clinics in the coming weeksThe clinics, to be located in Salt Lake City, Utah and Reno, Nevada will take KWC’s total clinic count to 14, forming part of the company’s plan to open 13 new ketamine infusion clinics across the country over the next 18 monthsFollowing Delic’s keynote ‘Meet Delic’ conference on Nov.…

Monday Dec 20, 2021 - 11:50 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase…

Friday Dec 17, 2021 - 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Announces Ketamine Wellness Centers Partnerships With Veterans Administration; Meet Delic Becomes World’s Largest Psychedelic Conference

Ketamine Wellness Centers (“KWC”) has partnered with the Veterans Administration (“VA”) Community Care Networks in Illinois and MinnesotaKWC will provide veterans with ketamine treatments for depression, chronic pain and PTSD at no out-of-pocket cost at these locationsMeet Delic was held on November 6 and 7 and became the world’s largest psychedelic wellness event Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and…

Tuesday Dec 14, 2021 - 12:35 pm

Meet Delic Sells Out, Becomes World’s Largest Psychedelic Conference

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) held the Meet Delic conference from November 6-7, 2021, in Las Vegas, NevadaThe event drew over 2,500 attendees, becoming the largest psychedelic wellness and business conference in the worldThe event featured over 60 expert speakers and thought leaders, including former NBA champion Lamar Odom and comedian Duncan TrussellOrganizers have announced new dates for Meet Delic 2022 in Las…

Friday Dec 10, 2021 - 9:31 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybinIn addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nauseaMydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing…

Thursday Dec 09, 2021 - 1:35 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgiaThis clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 studyIt is set to commence in 2022 and will involve 20 fibromyalgia patients…

Thursday Dec 09, 2021 - 1:24 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communitiesNew clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the serviceProgram’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the…

Articles

Articles Category: Psychedelics

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions